SPR 064
Alternative Names: Paclitaxel Prodrug; SPR064Latest Information Update: 28 Feb 2023
At a glance
- Originator University of California, Davis
- Developer Nuance Biotech; Sphaera Pharma
- Class Antineoplastics; Diterpenes; Paclitaxels; Taxanes
- Mechanism of Action Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for preclinical development in Solid-tumours in China (IV, Injection)
- 28 Feb 2023 No recent reports of development identified for preclinical development in Solid-tumours in China (SC, Injection)
- 25 Jan 2019 Preclinical trials in Solid tumours in China (IV)